Seeking novel targets for improving In Vivo macrophage-specific reverse cholesterol transport: Translating basic science into new therapies for the prevention and treatment of atherosclerosis

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 220-237

  Julve, Josep ^a,b   Llaverias, Gemma ^a,b   Blanco Vaca, Francisco ^a,b,c   Escolà Gil, Joan C ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; High density lipoprotein; Macrophages; Mice; Reverse cholesterol transport

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ABC TRANSPORTER A1; ABC TRANSPORTER G5; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTEROL ESTERASE; DALCETRAPIB; ETC 216; EZETIMIBE; FENOFIBRATE; FERULIC ACID; FISH OIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR AGONIST; MYCOPHENOLIC ACID; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; SIALOPROTEIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DISEASE PREDISPOSITION; DNA MODIFICATION; DRUG BINDING; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INTESTINE ABSORPTION; MACROPHAGE; NONHUMAN; REVERSE CHOLESTEROL TRANSPORT; REVIEW; SCIENCE;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; ENTEROHEPATIC CIRCULATION; HUMANS; LIPID REGULATING AGENTS; MACROPHAGES; MOLECULAR TARGETED THERAPY;

EID: 79951719402     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519264     Document Type: Review

References (303)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-9.
2. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-6.
3. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116: 3090-100.
4. Weisgraber KH, Bersot TP, Mahley RW, et al. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 1980; 66: 901-7.
5. Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66: 892-900.
6. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103: 1949-54.
7. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-16.
8. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-30.
9. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 153-60.
10. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
11. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
12. Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 2002; 99: 16237-42.
13. Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 2001; 6: D515-25.
14. Singh V, Tiwari RL, Dikshit M, Barthwal MK. Models to study atherosclerosis: a mechanistic insight. Curr Vasc Pharmacol 2009; 7: 75-109.
15. Reardon CA, Getz GS. Mouse models of atherosclerosis. Curr Opin Lipidol 2001; 12: 167-73.
16. Parolini C, Marchesi M, Chiesa G. HDL therapy for the treatment of cardiovascular diseases. Curr Vasc Pharmacol 2009; 7: 550-6.
17. Osono Y, Woollett LA, Marotti KR, et al. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA 1996; 93: 4114-9.
18. Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res 1998; 39: 2143-9.
19. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 2001; 276: 15641-9.
20. Jolley CD, Dietschy JM, Turley SD. Induction of bile acid synthesis by cholesterol and cholestyramine feeding is unimpaired in mice deficient in apolipoprotein AI. Hepatology 2000; 32: 1309-16.
21. Groen AK, Bloks VW, Bandsma RH, et al. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest 2001; 108: 843-50.
22. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 2199-211.
23. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J Biol Chem 2002; 277: 3801-4.
24. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-8.
25. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001; 42: 1586-93.
26. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25: 1057-64.
27. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003; 108: 661-3.
28. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117: 2216-24.
29. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009; 50(Suppl): S189-94.
30. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage- specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009; 206: 321-7.
31. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22: 336-45.
32. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATPbinding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347-51.
33. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352-5.
34. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113: 2548-55.
35. Calpe-Berdiel L, Rotllan N, Palomer X, et al. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta 2005; 1738: 6-9.
36. Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 2007; 27: 1837-42.
37. Mukhamedova N, Escher G, D'Souza W, et al. Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 2008; 49: 2312-22.
38. van Eck M, Bos IS, Kaminski WE, et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA 2002; 99: 6298-303.
39. Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002; 22: 630-7.
40. Van Eck M, Singaraja RR, Ye D, et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 929-34.
41. Zhao B, Fisher BJ, St Clair RW, et al. Redistribution of macrophage cholesteryl ester hydrolase from cytoplasm to lipid droplets upon lipid loading. J Lipid Res 2005; 46: 2114-21.
42. Zhao B, Song J, Chow WN, et al. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J Clin Invest 2007; 117: 2983-92.
43. Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 67-77.
44. Weibel GL, Joshi MR, Alexander ET, et al. Overexpression of human 15(S)-lipoxygenase-1 in RAW macrophages leads to increased cholesterol mobilization and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2009; 29: 837-42.
45. Navab M, Anantharamaiah GM, Reddy ST, et al. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-11.
46. Pirillo A, Uboldi P, Pappalardo G, et al. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1- mediated cholesterol efflux. Cardiovasc Res 2007; 75: 566-74.
47. Cyrus T, Witztum JL, Rader DJ, et al. Disruption of the 12/15- lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999; 103: 1597-604.
48. Cyrus T, Pratico D, Zhao L, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001; 103: 2277-82.
49. Reilly KB, Srinivasan S, Hatley ME et al. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 2004; 279: 9440-50.
50. Merched AJ, Ko K, Gotlinger KH, et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22: 3595-606.
51. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265-7.
52. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607-11.
53. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
54. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-Itransgenic rabbits. Circulation 1996; 94: 713-7.
55. Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99: 105-10.
56. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-22.
57. Kiss RS, McManus DC, Franklin V, et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1- dependent and -independent pathways. J Biol Chem 2003; 278: 10119-27.
58. Alexander ET, Weibel GL, Joshi MR, et al. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol 2009; 29: 1496-501.
59. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005; 97: 763-71.
60. Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med 2005; 37: 173-8.
61. Lee-Rueckert M, Kovanen PT. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Atherosclerosis 2006; 189: 8-18.
62. Asleh R, Miller-Lotan R, Aviram M, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006; 99: 1419-25.
63. Nielsen MJ, Moestrup SK. Receptor targeting of hemoglobin mediated by the haptoglobins: roles beyond heme scavenging. Blood 2009; 114: 764-71.
64. Levy AP, Roguin A, Hochberg I, et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 2000; 343: 969-70.
65. Asleh R, Guetta J, Kalet-Litman S, et al. Haptoglobin genotypeand diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005; 96: 435-41.
66. Levy AP, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007; 27: 134-40.
67. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
68. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-53.
69. Forte TM, Subbanagounder G, Berliner JA, et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and plateletactivating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 2002; 43: 477-85.
70. Zhu B, Reardon CA, Getz GS, Hui DY. Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice. Arterioscler Thromb Vasc Biol 2002; 22: 450-5.
71. Fazio S, Babaev VR, Murray AB, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94: 4647-52.
72. Van Eck M, Herijgers N, Vidgeon-Hart M, et al. Accelerated atherosclerosis in C57Bl/6 mice transplanted with ApoE-deficient bone marrow. Atherosclerosis 2000; 150: 71-80.
73. Fazio S, Babaev VR, Burleigh ME, et al. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J Lipid Res 2002; 43: 1602-9.
74. Ishiguro H, Yoshida H, Major AS, et al. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J Biol Chem 2001; 276: 36742-8.
75. Bellosta S, Mahley RW, Sanan DA, et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96: 2170-9.
76. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267: 1034-7.
77. Hasty AH, Linton MF, Brandt SJ, et al. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999; 99: 2571-6.
78. Zanotti I, Pedrelli M, Potì F, et al. Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2011; 31: 74-80.
79. Kozarsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20: 721-7.
80. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1732-8.
81. Ji Y, Wang N, Ramakrishnan R, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999; 274: 33398-402.
82. Amigo L, Mardones P, Ferrada C, et al. Biliary lipid secretion, bile acid metabolism, and gallstone formation are not impaired in hepatic lipase-deficient mice. Hepatology 2003; 38: 726-34.
83. Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387: 414-7.
84. Wang N, Arai T, Ji Y, et al. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem 1998; 273: 32920-6.
85. Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997; 94: 12610-5.
86. Varban ML, Rinninger F, Wang N, et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 1998; 95: 4619-24.
87. Trigatti B, Rayburn H, Vinals M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999; 96: 9322-7.
88. Arai T, Wang N, Bezouevski M, et al. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999; 274: 2366-71.
89. Ueda Y, Gong E, Royer L, et al. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 2000; 275: 20368-73.
90. Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90: 270-6.
91. Zhang Y, Da Silva JR, Reilly M, et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 2005; 115: 2870-4.
92. Zhao B, Natarajan R, Ghosh S. Human liver cholesteryl ester hydrolase: cloning, molecular characterization, and role in cellular cholesterol homeostasis. Physiol Genomics 2005; 23: 304-10.
93. Zhao B, Song J, Ghosh S. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J Lipid Res 2008; 49: 2212-7.
94. Yu L, Li-Hawkins J, Hammer RE, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 2002; 110: 671-80.
95. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006; 113: 90-7.
96. Calpe-Berdiel L, Rotllan N, Fievet C, et al. Liver X receptormediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J Lipid Res 2008; 49: 1904-11.
97. Zanotti I, Poti F, Pedrelli M, et al. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J Lipid Res 2008; 49: 954-60.
98. Briand F, Treguier M, Andre A, et al. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res 2010; 51(4): 763-70.
99. Briand F, Fuki I, Millar JS, et al. Both the peroxisome proliferatoractivated receptor d agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Translat Sci 2009; 2: 127-33.
100. Nishimoto T, Pellizzon MA, Aihara M, et al. Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol 2009; 29: 1502-8.
101. Wilund KR, Yu L, Xu F, et al. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/- mice. J Lipid Res 2004; 45: 1429-36.
102. Wilund KR, Yu L, Xu F, et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 2004; 24: 2326-32.
103. Yu L, York J, von Bergmann K, et al. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 2003; 278: 15565-70.
104. Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. Are LXRregulated genes a major molecular target of plant sterols/stanols? Atherosclerosis 2007; 195: 210-1.
105. Basso F, Freeman LA, Ko C, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J Lipid Res 2007; 48: 114-26.
106. Salen G, Shefer S, Nguyen L, et al. Sitosterolemia. J Lipid Res 1992; 33: 945-55.
107. Wang MD, Kiss RS, Franklin V, et al. Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathways. J Lipid Res 2007; 48: 633-45.
108. Out R, Jessup W, Le Goff W, et al. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2008; 102: 113-20.
109. Out R, Hoekstra M, Hildebrand RB, et al. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2295-300.
110. Ranalletta M, Wang N, Han S, et al. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 2006; 26: 2308-15.
111. Baldan A, Pei L, Lee R, et al. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 2006; 26: 2301-7.
112. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117: 3900-8.
113. Out R, Hoekstra M, Habets K, et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008; 28: 258-64.
114. Pennings M, Meurs I, Ye D, et al. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett 2006; 580: 5588-96.
115. Covey SD, Krieger M, Wang W, et al. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptornegative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2003; 23: 1589-94.
116. Van Eck M, Bos IS, Hildebrand RB, et al. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 2004; 165: 785-94.
117. Zhang W, Yancey PG, Su YR, et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2003; 108: 2258-63.
118. Huby T, Doucet C, Dachet C, et al. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest 2006; 116: 2767-76.
119. Chen W, Silver DL, Smith JD, Tall AR. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1- mediated cholesterol efflux in macrophages. J Biol Chem 2000; 275: 30794-800.
120. Huang ZH, Mazzone T. ApoE-dependent sterol efflux from macrophages is modulated by scavenger receptor class B type I expression. J Lipid Res 2002; 43: 375-82.
121. Van Eck M, Hoekstra M, Hildebrand RB, et al. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol 2007; 27: 2413-9.
122. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 2001; 42: 1727-39.
123. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002; 164: 1-13.
124. Kalopissis AD, Pastier D, Chambaz J. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol 2003; 14: 165-72.
125. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol 2004; 15: 247-53.
126. Escola-Gil JC, Marzal-Casacuberta A, Julve-Gil J, et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res 1998; 39: 457-62.
127. Escola-Gil JC, Julve J, Marzal-Casacuberta A, et al. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res 2001; 42: 241-8.
128. Escola-Gil JC, Julve J, Marzal-Casacuberta A, et al. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. J Lipid Res 2000; 41: 1328-38.
129. Warden CH, Hedrick CC, Qiao JH, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261: 469-72.
130. Rotllan N, Ribas V, Calpe-Berdiel L, et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2005; 25: e128-32.
131. Castellani LW, Navab M, Van Lenten BJ, et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100: 464-74.
132. Ribas V, Sanchez-Quesada JL, Anton R, et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 2004; 95: 789-97.
133. Dugue-Pujol S, Rousset X, Pastier D, et al. Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism. J Lipid Res 2006; 47: 2631-9.
134. Castellani LW, Nguyen CN, Charugundla S, et al. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J Biol Chem 2008; 283: 11633-44.
135. Julve J, Escola-Gil JC, Rotllan N, et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol 2010; 30: 232-8.
136. Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999; 274: 1814-20.
137. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
138. Lagor WR, Brown RJ, Toh SA, et al. Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler Thromb Vasc Biol 2009; 29: 40-6.
139. Asztalos BF, Schaefer EJ, Horvath KV, et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res 2007; 48: 592-9.
140. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 2005; 178: 217-30.
141. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB, Jr. Lecithin- cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2000; 11: 267-75.
142. Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005; 16: 139-45.
143. Tanigawa H, Billheimer JT, Tohyama J, et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 2009; 120: 160-9.
144. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997; 3: 744-9.
145. Mehlum A, Muri M, Hagve TA, et al. Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against dietinduced atherosclerosis. APMIS 1997; 105: 861-8.
146. Furbee JW, Jr., Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis 2002; 165: 89-100.
147. Foger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999; 274: 36912-20.
148. Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferasedeficient mice. J Biol Chem 2001; 276: 15090-8.
149. Furbee JW, Jr., Sawyer JK, Parks JS. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 2002; 277: 3511-9.
150. Ng DS, Maguire GF, Wylie J, et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002; 277: 11715-20.
151. Calabresi L, Favari E, Moleri E, et al. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 2009; 204: 141-6.
152. Gomaraschi M, Basilico N, Sisto F, et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 2005; 1736: 136-43.
153. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009; 120: 628-35.
154. Holleboom AG, Kuivenhoven JA, Vergeer M, et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res 51: 416-21.
155. Day JR, Albers JJ, Lofton-Day CE, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem 1994; 269: 9388-91.
156. Albers JJ, Wolfbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995; 1258: 27-34.
157. Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993; 268: 4032-6.
158. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993; 268: 23098-105.
159. van Haperen R, van Tol A, Vermeulen P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20: 1082-8.
160. van Haperen R, van Tol A, van Gent T, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277: 48938-43.
161. Lie J, de Crom R, van Gent T, et al. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 2004; 45: 805-11.
162. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003; 23: 1601-7.
163. Samyn H, Moerland M, van Gent T, et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis 2009; 204: 429-34.
164. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7: 847-52.
165. Yan D, Navab M, Bruce C, et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 2004; 45: 1852-8.
166. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 1857-62.
167. Schlitt A, Blankenberg S, Bickel C, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009; 50: 723-9.
168. O'Brien KD, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003; 108: 270-4.
169. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003; 44: 1453-61.
170. Liu R, Hojjati MR, Devlin CM, et al. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 190-6.
171. Valenta DT, Ogier N, Bradshaw G, et al. Atheroprotective potential of macrophage-derived phospholipid transfer protein in lowdensity lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 2006; 26: 1572-8.
172. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK. Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J Lipid Res 2008; 49: 24-32.
173. van Haperen R, Samyn H, Moerland M, et al. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One 2008; 3: e2255.
174. Ogier N, Klein A, Deckert V, et al. Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Arterioscler Thromb Vasc Biol 2007; 27: 2407-12.
175. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010; 31(2): 149-64.
176. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.
177. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45: 948-53.
178. Harada LM, Amigo L, Cazita PM, et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 2007; 191(2): 313-8.
179. Rotllan N, Calpe-Berdiel L, Guillaumet-Adkins A, et al. CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Atherosclerosis 2008; 196: 505-13.
180. Tanigawa H, Billheimer JT, Tohyama J, et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007; 116: 1267-73.
181. Tchoua U, D'Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 2008; 77: 732-9.
182. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-5.
183. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96: 2071-4.
184. Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19: 1105-10.
185. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006; 26: 2552-9.
186. Van Eck M, Ye D, Hildebrand RB, et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 2007; 100: 678-85.
187. Ma K, Cilingiroglu M, Otvos JD, et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 2003; 100: 2748-53.
188. Jaye M, Krawiec J. Endothelial lipase and HDL metabolism. Curr Opin Lipidol 2004; 15: 183-9.
189. Brown RJ, Edmondson AC, Griffon N, et al. A naturally occurring variant of endothelial lipase associated with elevated HDL exhibits impaired synthesis. J Lipid Res 2009; 50: 1910-6.
190. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119: 1042-50.
191. Jaye M, Lynch KJ, Krawiec J, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999; 21: 424-8.
192. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111: 347-55.
193. Jin W, Wang X, Millar JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007; 6: 129-36.
194. Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-92.
195. Ko KW, Paul A, Ma K, et al. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res 2005; 46: 2586-94.
196. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-98.
197. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008; 5: 542-53.
198. Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009; 20: 505-11.
199. Nicholls SJ, Tuzcu EM. High-density lipoprotein and atheroma monitoring. Curr Opin Cardiol 2008; 23: 386-92.
200. Chiesa G, Parolini C, Sirtori CR. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008; 23: 379-85.
201. Kakafika A, Athyros VG, Tziomalos K, et al. High density lipoprotein cholesterol and statin trials. Curr Med Chem 2008; 15: 2265-70.
202. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol 2009; 24: 473-82.
203. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
204. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27: 257-60.
205. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009; 120: 2414-20.
206. Mowri HO, Patsch JR, Ritsch A, et al. High density lipoproteins with differing apolipoproteins: relationships to postprandial lipemia, cholesteryl ester transfer protein, and activities of lipoprotein lipase, hepatic lipase, and lecithin: cholesterol acyltransferase. J Lipid Res 1994; 35: 291-300.
207. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006; 116: 1435-42.
208. Kee P, Caiazza D, Rye KA, et al. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscler Thromb Vasc Biol 2006; 26: 884-90.
209. de Haan W, de Vries-van der Weij J, van der Hoorn JW, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008; 117: 2515-22.
210. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebocontrolled phase I studies. Lancet 2007; 370: 1907-14.
211. Krishna R, Bergman A, Jin B, et al. Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects. Clin Pharmacol Ther 2008; 84(6): 679-83.
212. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465-73.
213. Rennings AJ, Stalenhoef AF. JTT-705: is there still future for a CETP inhibitor after torcetrapib? Expert Opin Investig Drugs 2008; 17: 1589-97.
214. Hermann F, Enseleit F, Spieker LE, et al. Cholesterylestertransfer Protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res 2009; 123(3): 460-5.
215. Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009; 24: 364-71.
216. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
217. Brewer HB, Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J 2004; 148: S14-8.
218. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3: 540-7.
219. Bloedon LT, Dunbar RL, Duffy D, et al. Oral administration of the apolipoprotein A-1 mimetic peptide D-4F in humans with CHD improves HDL anti-inflammatory function after a single dose. Circulation 2006; 114: 288.
220. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90: 1935-41.
221. Soma MR, Donetti E, Parolini C, et al. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995; 76: 405-11.
222. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein Edeficient mice. Circulation 1998; 97: 780-5.
223. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002; 90: 974-80.
224. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1- palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008; 51: 1098-103.
225. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-82.
226. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002; 41: 2089-96.
227. Gomaraschi M, Baldassarre D, Amato M, et al. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation 2007; 116: 2165-72.
228. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107: 2944-8.
229. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-2.
230. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves highdensity lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-20.
231. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-32.
232. Van Lenten BJ, Wagner AC, Navab M, et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007; 48: 2344-53.
233. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 2005; 97: 524-32.
234. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997; 272: 3137-40.
235. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
236. Repa JJ, Berge KE, Pomajzl C, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002; 277: 18793-800.
237. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000; 275: 28240-5.
238. Chen JY, Levy-Wilson B, Goodart S, Cooper AD. Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet. J Biol Chem 2002; 277: 42588-95.
239. Wang N, Ranalletta M, Matsuura F, et al. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 2006; 26: 1310-6.
240. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-14.
241. Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003; 536: 6-11.
242. Joseph SB, McKilligin E, Pei L et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9.
243. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25: 135-42.
244. Kruit JK, Plosch T, Havinga R, et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005; 128: 147-56.
245. van der Veen JN, van Dijk TH, Vrins CL, et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem 2009; 284: 19211-9.
246. van der Velde AE, Vrins CL, van den Oever K, et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007; 133: 967-75.
247. van der Velde AE, Vrins CL, van den Oever K, et al. Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295: G203-G208.
248. Scott J. The liver X receptor and atherosclerosis. N Engl J Med 2007; 357: 2195-7.
249. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-57.
250. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
251. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
252. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human vs. mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97: 2408-16.
253. Duez H, Lefebvre B, Poulain P, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator- activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005; 25: 585-91.
254. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-8.
255. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004; 114: 1564-76.
256. Rotllan N, Llaverías G, Julve J, et al. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim Biophys Acta 2010 doi:10.1016/j.bbalip.2010.11.006.
257. Duez H, Chao YS, Hernandez M, et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 2002; 277: 48051-7.
258. Sprecher DL, Massien C, Pearce G, et al. Triglyceride: highdensity lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007; 27: 359-65.
259. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333-6.
260. Oliver WR, Jr., Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
261. Graham TL, Mookherjee C, Suckling KE, et al. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005; 181: 29-37.
262. Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008; 105: 4271-6.
263. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
264. Brown WV. Cholesterol absorption inhibitors: defining new options in lipid management. Clin Cardiol 2003; 26: 259-64.
265. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.
266. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-60.
267. Davis HR, Jr., Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 2032-8.
268. Davis HR, Jr., Hoos LM, Tetzloff G, et al. Deficiency of Niemann- Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 841-9.
269. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-7.
270. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 1296-7.
271. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
272. Greenberg ME, Smith JD, Sehayek E. Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Arterioscler Thromb Vasc Biol 2009; 29: 1745-50.
273. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006; 48: 715-20.
274. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-55.
275. Hill AM, Fleming JA, Kris-Etherton PM. The role of diet and nutritional supplements in preventing and treating cardiovascular disease. Curr Opin Cardiol 2009; 24: 433-41.
276. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: e20-30.
277. Marmillot P, Rao MN, Liu QH, et al. Effect of dietary omega-3 fatty acids and chronic ethanol consumption on reverse cholesterol transport in rats. Metabolism 2000; 49: 508-12.
278. Le Beyec J, Benetollo C, Chauffeton V et al. The -911/+25 sequence of human apolipoprotein A-II promoter is sufficient to confer liver restricted expression, developmental changes and response to a high fat diet in transgenic mice. Transgenics 1998; 2: 211-20.
279. Wang HH, Hung TM, Wei J, Chiang AN. Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res 2004; 61: 169-76.
280. Casos K, Saiz MP, Ruiz-Sanz JI, Mitjavila MT. Atherosclerosis prevention by a fish oil-rich diet in apoE(-/-) mice is associated with a reduction of endothelial adhesion molecules. Atherosclerosis 2008; 201: 306-17.
281. Adan Y, Shibata K, Ni W, et al. Concentration of serum lipids and aortic lesion size in female and male apo E-deficient mice fed docosahexaenoic acid. Biosci Biotechnol Biochem 1999; 63: 309-13.
282. Zampolli A, Bysted A, Leth T, et al. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis 2006; 184: 78-85.
283. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. The J-shaped effect of coffee consumption on the risk of developing acute coronary syndromes: the CARDIO2000 case-control study. J Nutr 2003; 133: 3228-32.
284. Lopez-Garcia E, van Dam RM, Li TY, et al. The relationship of coffee consumption with mortality. Ann Intern Med 2008; 148: 904-14.
285. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, et al. Coffee consumption and risk of stroke in women. Circulation 2009; 119: 1116-23.
286. Uto-Kondo H, Ayaori M, Ogura M, et al. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Circ Res 2010; 106(4): 779-87.
287. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009; 35: 98-104.
288. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451: 904-13.
289. Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009; 16: 667-75.
290. Navab M, Anantharamaiah GM, Fogelman AM. The role of highdensity lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15: 158-61.
291. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-45.
292. Annema W, Nijstad N, Tolle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response, but not group IIA secretory phospholipase A2. J Lipid Res 2010; 51: 743-54.
293. Moazed TC, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-41.
294. Liu L, Hu H, Ji H, et al. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Mol Cell Biochem 2000; 215: 123-8.
295. Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA, et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovasc Res 2002; 56: 269-76.
296. Hauer AD, de Vos P, Peterse N, et al. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr- /- mice. Cardiovasc Res 2006; 69: 280-8.
297. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human non-alcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-9.
298. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005; 25: 193-7.
299. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114: 623-9.
300. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
301. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapinecontaining antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14.
302. van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003; 16: 19-23.
303. Tohyama J, Billheimer JT, Fuki IV, et al. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis 2009; 204: 418-23.